The prevalence of anti-HCV antibodies among patients on dialysis is consistently higher than in healthy populations, suggesting that dialysis patients may be at higher risk of acquiring HCV infection. The aim of our study was to determinate the prevalence of anti-HCV antibodies in patients whom attend to dialysis facilities in Cali, Colombia. 999 patients were tested using the third generation enzyme linked immunosorbent assay (ELISA-3), 29 patients were Anti-HCV positive (2,9% prevalence). All Anti-HCV positive patients were tested to detect the HCV- RNA using a real time-PCR qualitative test (Amplicor Monitor 2.0 Roche Molecular Systems), 26/29 patients were HCV-RNA positive (89%). Conclusions: The prevalence of anti-HCV antibodies in the dialysis facilities in Cali (2.9%) is very similar to the prevalence reported by industrialized countries.